These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 31611440

  • 1. The role of p53, Ki-67 and laminin expression in the differential diagnosis of keratoacanthoma and well-differentiated SCC.
    Turan G, Altun E, Aslan F, Kulahci O.
    Indian J Pathol Microbiol; 2019; 62(4):561-565. PubMed ID: 31611440
    [Abstract] [Full Text] [Related]

  • 2. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors.
    Cain CT, Niemann TH, Argenyi ZB.
    Am J Dermatopathol; 1995 Aug; 17(4):324-31. PubMed ID: 8600793
    [Abstract] [Full Text] [Related]

  • 3. The nuclear factor kappa B p50 subunit and cortactin as markers to distinguish between keratoacanthoma and well-differentiated squamous cell carcinoma.
    Fujii M, Honma M, Takahashi H, Ishida-Yamamoto A, Iizuka H.
    Clin Exp Dermatol; 2011 Oct; 36(7):788-92. PubMed ID: 21883393
    [Abstract] [Full Text] [Related]

  • 4. Assessment of syndecan-1 (CD138) and Ki-67 expression for differentiating keratoacanthoma and squamous cell carcinoma.
    Lammoglia-Ordiales L, Toussaint-Caire S, Contreras-Barrera M, Fonte-Avalos V, Rodriguez-Carreón AA, Rivera-Macias S, Dominguez-Cherit J.
    J Drugs Dermatol; 2013 Mar; 12(3):e53-8. PubMed ID: 23545927
    [Abstract] [Full Text] [Related]

  • 5. The potential role of abnormal E-cadherin and alpha-, beta- and gamma-catenin immunoreactivity in the determination of the biological behaviour of keratoacanthoma.
    Papadavid E, Pignatelli M, Zakynthinos S, Krausz T, Chu AC.
    Br J Dermatol; 2001 Oct; 145(4):582-9. PubMed ID: 11703284
    [Abstract] [Full Text] [Related]

  • 6. p53 protein expression and cell proliferation in non-neoplastic and neoplastic proliferative skin diseases.
    Batinac T, Zamolo G, Jonjić N, Gruber F, Petrovecki M.
    Tumori; 2004 Oct; 90(1):120-7. PubMed ID: 15143984
    [Abstract] [Full Text] [Related]

  • 7. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma.
    Kerschmann RL, McCalmont TH, LeBoit PE.
    Arch Dermatol; 1994 Feb; 130(2):181-6. PubMed ID: 8304756
    [Abstract] [Full Text] [Related]

  • 8. Differential diagnosis of keratoacanthomas and squamous cell carcinomas: diagnostic value of DNA image cytometry and p53 expression.
    Pilch H, Weiss J, Heubner C, Heine M.
    J Cutan Pathol; 1994 Dec; 21(6):507-13. PubMed ID: 7699117
    [Abstract] [Full Text] [Related]

  • 9. Squamous cell carcinoma arising in association with verruca vulgares and HPV-2: a clinicopathologic study with p16 and p53 immunohistochemical studies and human papillomavirus in situ hybridization studies.
    Ruhoy SM, Guinee DG, Nuovo G.
    Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):253-61. PubMed ID: 24717230
    [Abstract] [Full Text] [Related]

  • 10. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
    Kanzaki A, Kudo M, Ansai S, Peng WX, Ishino K, Yamamoto T, Wada R, Fujii T, Teduka K, Kawahara K, Kawamoto Y, Kitamura T, Kawana S, Saeki H, Naito Z.
    Int J Oncol; 2016 Mar; 48(3):1007-15. PubMed ID: 26782292
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Role of p16, p21, p27, p53 and Ki-67 Expression in the Differential Diagnosis of Cutaneous Squamous Cell Carcinomas and Keratoacanthomas: An Immunohistochemical Study.
    Bedir R, Güçer H, Şehitoğlu İ, Yurdakul C, Bağcı P, Üstüner P.
    Balkan Med J; 2016 Mar; 33(2):121-7. PubMed ID: 27403379
    [Abstract] [Full Text] [Related]

  • 15. Invasive squamous cell carcinoma initially diagnosed as a giant keratoacanthoma.
    Goldenhersh MA, Olsen TG.
    J Am Acad Dermatol; 1984 Feb; 10(2 Pt 2):372-8. PubMed ID: 6368620
    [Abstract] [Full Text] [Related]

  • 16. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry.
    Biesterfeld S, Josef J.
    Anticancer Res; 2002 Feb; 22(5):3019-23. PubMed ID: 12530035
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Glut-1 expression and in situ CD1a/CD57 immunologic deficit in keratoacanthoma and squamous cell carcinoma of immunocompetent patients.
    Cabibi D, Aragona F, Guarnotta C, Rodolico V, Zerilli M, Belmonte B, Schillaci L, Aragona F.
    Appl Immunohistochem Mol Morphol; 2011 May; 19(3):239-45. PubMed ID: 21475039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.